UCSF Enters Drug Discovery Agreement with Genentech

The University of California, San Francisco, and Genentech, Inc., have signed an agreement to discover drug candidates for neurodegenerative diseases. Genentech will provide funding and will collaborate with the UCSF team to identify small molecules at the UCSF Small Molecule Discovery Center. Genentech has recently begun making overtures into the ALS space, including a license and option agreement with NeuroNova for the use of VEGF as a potential ALS treatment.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail